- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.96 Å
- Oligo State
- hetero-2-2-mer
- Ligands
- 3 x 1PG: 2-(2-{2-[2-(2-METHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHANOL(Non-covalent)
- 2 x MYR: MYRISTIC ACID(Covalent)
MYR.2: 14 residues within 4Å:- Chain A: Y.16, A.18, V.35, V.103, T.119, K.131, C.154, M.157, F.160, I.161, L.177, F.180, I.182, F.202
11 PLIP interactions:11 interactions with chain A- Hydrophobic interactions: A:A.18, A:V.35, A:V.103, A:T.119, A:M.157, A:F.160, A:I.161, A:L.177, A:F.180, A:F.202
- Hydrogen bonds: A:C.154
MYR.5: 13 residues within 4Å:- Chain B: Y.16, A.18, V.35, V.103, T.119, K.131, C.154, M.157, F.160, L.177, F.180, I.182, F.202
10 PLIP interactions:10 interactions with chain B- Hydrophobic interactions: B:A.18, B:V.35, B:V.103, B:T.119, B:M.157, B:F.160, B:L.177, B:F.180, B:F.202
- Hydrogen bonds: B:C.154
- 4 x WCF: 4-[(2~{S})-5-chloranyl-6-fluoranyl-2-phenyl-2-[(2~{S})-pyrrolidin-2-yl]-3~{H}-1-benzofuran-4-yl]-5-fluoranyl-6-(2-hydroxyethyloxy)-~{N}-methyl-pyridine-3-carboxamide(Non-covalent)
WCF.3: 14 residues within 4Å:- Chain A: V.52, Q.56, I.57, K.60, L.82, K.84, F.85, W.86, E.178, T.181, V.201, F.202, E.203, Y.216
12 PLIP interactions:12 interactions with chain A- Hydrophobic interactions: A:K.84, A:W.86, A:E.178, A:V.201, A:V.201, A:E.203
- Hydrogen bonds: A:Q.56, A:Y.216
- Water bridges: A:K.84, A:K.84, A:F.202
- pi-Cation interactions: A:K.60
WCF.6: 14 residues within 4Å:- Chain B: V.52, Q.56, I.57, K.60, L.82, K.84, F.85, W.86, E.178, T.181, V.201, F.202, E.203, Y.216
13 PLIP interactions:13 interactions with chain B- Hydrophobic interactions: B:K.84, B:K.84, B:W.86, B:E.178, B:V.201, B:V.201, B:E.203
- Hydrogen bonds: B:Q.56, B:Y.216
- Water bridges: B:K.84, B:K.84, B:F.202
- pi-Cation interactions: B:K.60
WCF.8: 15 residues within 4Å:- Chain C: V.52, Q.56, I.57, K.60, F.61, L.82, K.84, F.85, W.86, E.178, T.181, V.201, F.202, E.203, Y.216
12 PLIP interactions:12 interactions with chain C- Hydrophobic interactions: C:K.84, C:W.86, C:E.178, C:V.201, C:V.201, C:E.203
- Hydrogen bonds: C:Q.56, C:E.203, C:Y.216
- Water bridges: C:K.84, C:F.202
- pi-Cation interactions: C:K.60
WCF.11: 14 residues within 4Å:- Chain D: V.52, Q.56, I.57, K.60, L.82, K.84, F.85, W.86, E.178, T.181, V.201, F.202, E.203, Y.216
12 PLIP interactions:12 interactions with chain D- Hydrophobic interactions: D:K.84, D:W.86, D:E.178, D:V.201, D:V.201, D:E.203, D:E.203
- Hydrogen bonds: D:Q.56, D:Y.216
- Water bridges: D:K.60, D:F.202
- pi-Cation interactions: D:K.60
- 2 x DMS: DIMETHYL SULFOXIDE(Non-functional Binders)
DMS.7: 6 residues within 4Å:- Chain B: Y.136
- Chain C: R.138, L.139, E.140, N.141
- Chain D: Y.136
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:N.141
- Water bridges: C:G.142
DMS.10: 6 residues within 4Å:- Chain A: Y.136
- Chain C: Y.136
- Chain D: R.138, L.139, E.140, N.141
3 PLIP interactions:2 interactions with chain D, 1 interactions with chain C- Hydrogen bonds: D:N.141
- Water bridges: D:G.142
- pi-Cation interactions: C:Y.136
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Chapeau, E.A. et al., Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers. Nat Cancer (2024)
- Release Date
- 2024-04-10
- Peptides
- Transcriptional enhancer factor TEF-5: AB
Transcriptional enhancer factor TEF-5: CD - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
D
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.96 Å
- Oligo State
- hetero-2-2-mer
- Ligands
- 3 x 1PG: 2-(2-{2-[2-(2-METHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHANOL(Non-covalent)
- 2 x MYR: MYRISTIC ACID(Covalent)
- 4 x WCF: 4-[(2~{S})-5-chloranyl-6-fluoranyl-2-phenyl-2-[(2~{S})-pyrrolidin-2-yl]-3~{H}-1-benzofuran-4-yl]-5-fluoranyl-6-(2-hydroxyethyloxy)-~{N}-methyl-pyridine-3-carboxamide(Non-covalent)
- 2 x DMS: DIMETHYL SULFOXIDE(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Chapeau, E.A. et al., Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers. Nat Cancer (2024)
- Release Date
- 2024-04-10
- Peptides
- Transcriptional enhancer factor TEF-5: AB
Transcriptional enhancer factor TEF-5: CD - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
D